Pancreas Cancer Clinical Trials 2022
Browse 32 Pancreas Cancer Medical Studies Across 51 Cities
1 Phase 3 Trial · 89 Pancreas Cancer Clinics
What Are Pancreas Cancer Clinical Trials?
According to cancer.gov, pancreatic cancer is a cancer that starts in the pancreas caused by malignant cells forming in the tissues of the pancreas. Clinical trials for Pancreatic cancer are research studies that investigate treatments or a combination of treatments that can benefit those diagnosed with Pancreatic cancer.
The Food and Drug Adminstration reviews and analyzes data from successful clinical trials and determines whether the treatment can be approved for a disease like pancreatic cancer.
Why Is Pancreas Cancer Being Studied Through Clinical Trials?
The World Cancer Research Fund lists pancreatic cancer as the 12th most common forms of cancer worldwide, and those diagnosed with pancreatic cancer have a five-year survival rate. Cancer.net states that an estimated 495,773 people were diagnosed with pancreatic cancer in 2020, and this figure increases by 1% each year.
The American Cancer Association estimates that 62,210 people will be diagnosed with pancreatic cancer in the United States yearly. The average lifetime risk of being diagnosed with pancreatic cancer is 1 in 64, but this number can be affected by certain risk factors.
Clinical trials for pancreatic cancer are necessary because they give patients access to novel treatments. In addition, clinical trials help progress research which leads to better outcomes, and better treatment options for those battling pancreatic cancer.
What Are The Types Of Treatments Available For Pancreas Cancer?
The current treatments used to treat pancreatic cancer include chemotherapy, radiation, surgery, targeted therapy, and immunotherapy.
Some of the most recent clinical trials for pancreatic cancer include:
- Plerixafor and Cemiplimab (for the treatment of metastatic pancreatic cancer). The Plerixafor blocks a protein called CXCR4, which is believed to help cancer escape from the immune system. Cemiplimab aids the immune system in helping it recognize and destroy tumor cells.
- Elraglusib, Retifanlimab, Gemcitabine, and Nab-Paclitaxel (for treating advanced pancreatic cancer). The combination of these treatments works to shrink tumors in patients with pancreatic cancer.
- Retifanlimab (for the treatment of unresectable or metastatic pancreatic cancer). This treatment is for patients with inoperable pancreatic cancer. Retifanlimabhis helps the immune system attack cancer and may prevent new tumors and cancer cells from growing and spreading.
What Are Some Of The Breakthrough Clinical Trials For Pancreas Cancer?
There have been a few breakthrough clinical trials for pancreatic cancer in recent years. Some of these include:
2022: Chemo Immunotherapy Combination – A study of a combination of chemotherapy and immunotherapy is being led by researchers at Perelman School of Medicine and has shown promising results thus far. This treatment is aimed at unleashing the immune system's anticancer capacity and has shown a one-year survival rate of 57.7% compared to 35% when chemotherapy is used alone.
2022: AMP945 – A clinical trial conducted by the Garvan Institute of Medical Research has shown that a new targeted treatment for pancreatic cancer can make tumors more susceptible to chemotherapy and can increase patient survival rates. The AMP945 drug works to help break down the defenses in pancreatic tumors and looks to be a promising treatment for pancreatic cancer.
According to clinicaltrials.gov, one clinical trial that is being studied for those with stage IV pancreatic cancer is the MDX-010 trial. The MDX-010 treatment is a drug treatment that helps immune cells kill cancer cells.
Who Are Some Of The Key Opinion Leaders/Researchers/Institutions Conducting Pancreas Cancer Trial Research?
Steven A. Rosenberg is a key researcher in the MDX-010 treatment for patients with stage IV pancreatic cancer. Steven Rosenberg is widely known in the field of cancer research and clinical trials and has spent 40 years studying immunotherapy treatments for cancer, including pancreatic cancer.
Christopher Wolfgang is a pancreatic cancer researcher and has shown great interest in the biological behavior of pancreatic cancer. He has been an author of 463 peer-reviewed articles in the last 15 years and is well known for his approach to helping pancreatic patients overcome steep odds.
About The Author
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.